Patient Registry of Roflumilast In Real Life
Launched by ASTRAZENECA · Dec 13, 2013
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
The drug being tested in this observational study design is called roflumilast, but not as an therapeutic intervention. Roflumilast is approved for and marketed globally for maintenance treatment of severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.
This study will capture real life data and demonstrate the performance of roflumilast in a standard clinical practice. The study will enroll approximately 1350 (EU)+600(North Asia) patients. This multi-centre tri...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent to the data collection
- • Roflumilast (Daxas®) treatment initiated in Roflumilast (Daxas®) naïve patients at the time of registry
- Exclusion Criteria:
- • There are no exclusion criteria per se. However it is expected that patients are treated according to locally approved marketing authorisation.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Sofia, , Bulgaria
Seoul, , Korea, Republic Of
Suwon, , Korea, Republic Of
Athens, , Greece
Bratislava, , Slovakia
Michalovce, , Slovakia
Gwangju, , Korea, Republic Of
Bergen, , Norway
Pleven, , Bulgaria
Nitra, , Slovakia
Patras, , Greece
Thessaloniki, , Greece
Fredrikstad, , Norway
Sandvika, , Norway
Tonsberg, , Norway
Busan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Banska Bystrica, , Slovakia
Presov, , Slovakia
Edessa, , Greece
Elverum, , Norway
Volos, , Greece
Tønsberg, , Norway
Bardejov, , Slovakia
Spisska Nova Ves, , Slovakia
Skien, , Norway
Arendal, , Norway
Povazska Bystrica, , Slovakia
Jeonju, , Korea, Republic Of
Katerini, , Greece
Sturovo, , Slovakia
Malacky, , Slovakia
Vratsa, , Bulgaria
Razgrad, , Bulgaria
Troyan, , Bulgaria
Agrinio, , Greece
Herakleion Crete, , Greece
Imitos, , Greece
Kaisariani, , Greece
Kalamaria, , Greece
Nafpaktos, , Greece
Peiraias, , Greece
Peristeri, , Greece
Ptolemaida, , Greece
Pyrgos, , Greece
Kongsvinger, , Norway
Straume, , Norway
Humenne, , Slovakia
Revuca, , Slovakia
Senica, , Slovakia
Topolcany, , Slovakia
Patients applied
Trial Officials
AstraZeneca AstraZeneca
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials